What is the Abigail hormone replacement therapy regimen for a generally healthy perimenopausal woman (age 45‑55) without contraindications such as estrogen‑dependent cancer, thromboembolic disease, uncontrolled hypertension, liver disease, or active cardiovascular disease?

There is no such thing as "Abigail hormone replacement therapy"

The term "Abigail" does not refer to any recognized hormone replacement therapy regimen, formulation, or protocol in medical literature or clinical practice guidelines. You may be referring to a different term or brand name.

Standard Perimenopausal Hormone Therapy Approach

For a healthy perimenopausal woman (age 45-55) with bothersome vasomotor symptoms and no contraindications, initiate FDA-approved estrogen plus progestogen therapy (EPT) if she has a uterus, or estrogen-only therapy (ET) if she does not 1, 2.

Specific Regimen Selection

Preferred first-line approach:

• Transdermal estradiol (patch or gel) combined with micronized progesterone for women with a uterus 1
• This combination minimizes venous thromboembolism (VTE) risk compared to oral formulations 3, 4

Alternative FDA-approved options include:

• Oral conjugated equine estrogens (CEE) with medroxyprogesterone acetate (MPA)
• CEE/bazedoxifene combination (where available) 1
• Various other FDA-approved estrogen/progestogen combinations

Progestogen Dosing for Endometrial Protection

For women with an intact uterus taking estrogen:

• Continuous daily progestogen (achieves amenorrhea but may have adverse breast outcomes) 2
• Cyclic progestogen for 10-14 days per month (causes withdrawal bleeding) 2
• Long-cycle therapy: 14 days every 3 months (reduces progestogen exposure, though efficacy less established) 2

Critical caveat: Never use unopposed estrogen in women with a uterus due to endometrial cancer risk 2.

Dosing Strategy

• Start with the lowest effective dose 2, 4
• Use for the shortest duration necessary to control symptoms 2, 5
• Consider dose reduction with advancing age 2
• Revisit the decision to continue annually with shared decision-making 1

Route-Specific Considerations

Transdermal estradiol is preferred when:

• Moderate cardiovascular risk exists (avoids hepatic first-pass effect) 1
• VTE risk is a concern 3, 4
• The patient is over 60 or more than 10 years past menopause 1

Oral formulations may be acceptable when:

• The woman is under 60 and within 10 years of menopause
• No elevated cardiovascular or VTE risk exists 4

Timing Window ("Window of Opportunity")

The benefit-risk ratio is most favorable when therapy is initiated:

• Before age 60, AND
• Within 10 years of menopause onset 1, 4

After this window, absolute risks of coronary heart disease, stroke, VTE, and dementia increase significantly 4, 6.

Contraindications to Screen For

Before initiating therapy, confirm absence of:

• Estrogen-dependent cancers (breast, endometrial)
• Active or history of thromboembolic disease
• Active cardiovascular disease or stroke
• Uncontrolled hypertension
• Active liver disease
• Unexplained vaginal bleeding 5

Monitoring Requirements

• Evaluate any unscheduled bleeding to rule out endometrial pathology 1
• Emphasize adherence to age-appropriate breast cancer screening (risk increases after 5+ years of EPT) 1
• Annual reassessment of treatment goals and evolving risks 1

Common Pitfall to Avoid

Do not use custom-compounded "bioidentical" hormones—only FDA-approved preparations should be prescribed 1. Despite marketing claims, compounded hormones lack standardization, quality control, and safety data.

If you meant a specific brand name or regimen by "Abigail," please clarify so I can provide targeted information about that particular formulation.